Radiopharmaceuticals for targeting the angiogenesis marker alpha(v)beta(3).
A common feature of solid tumors is the formation of new blood vessels (angiogenesis) within the tumor. A receptor called alpha(v)beta(3) is found on endothelial cells lining newly growing blood vessels at a higher density than on mature blood vessels. This receptor may provide a target for radioligands to permit imaging of a wide variety of solid tumors. The radioligands may range from macromolecules such as native ligands or monoclonal antibodies, to small proteins to very small peptides. The differing characteristics of these bio-molecules have an affect on target delivery and clearance time.
McQuade
P
P
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
KnIght
L C
LC
D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism*; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000378:metabolism*; D009369:Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000000981:diagnostic imaging* / Q000378:metabolism*; D011868:Radioisotopes / Q000145:classification / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000145:classification / Q000493:pharmacokinetics
D014408:Biomarkers, Tumor; D039302:Integrin alphaVbeta3; D011868:Radioisotopes; D019275:Radiopharmaceuticals